It is currently Thu Oct 23, 2014 1:43 pm

News News of Aubagio (teriflunomide)

Site map of Aubagio (teriflunomide) » Forum : Aubagio (teriflunomide)

Aubagio is an oral treatment approved for MS.

Oral MS treatment Aubagio® approved for RRMS in Canada

Genzyme, a Sanofi company, announced today that Health Canada has approved Aubagio® (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

"There are many patients who simply cannot tolerate injections and have had no simple, effective, once daily oral medication until now," said Dr. Mark Freedman, Director, Multiple Sclerosis Research Unit and Professor ...
Read more : Oral MS treatment Aubagio® approved for RRMS in Canada | Views : 8285 | Replies : 0


Re: Aubagio

Hi I'm new to the site and I just begin to take Aubagio 3 days ago. So far so good. I'm not experiencing any side effects as of now( thanking God) I left Copaxone because of injection sites I was literally running out of room. In the last MRI 9/24/13 I had a new lesion that has formed. It's located in the posterior right centrum semiovale. Uncertain about medical terms but it doesn't sound good. ...
Read more : Re: Aubagio | Views : 2592 | Replies : 8


Aubagio(R) significantly reduced risk of relapse & lesions

Aubagio(R) significantly reduced risk of new clinical relapse or MRI lesion in MS study

Genzyme, a Sanofi company , announced positive new data from the TOPIC study of its once-daily, oral Aubagio(R) (teriflunomide). These new data, presented today at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS), include the following:

-- Aubagio 14 mg significantly reduced the risk of a new clinical relapse or MRI lesion over the ...
Read more : Aubagio(R) significantly reduced risk of relapse & lesions | Views : 907 | Replies : 0


NICE demands more data for Sanofi's oral MS drug Aubagio

Sanofi will need to provide more evidence supporting the effectiveness of its oral multiple sclerosis drug Aubagio if it wants the treatment to be recommended for use on the NHS in England and Wales.

The National Institute for Health and Care Excellence (NICE), which assesses the cost-effectiveness of treatments for NHS use, released initial draft guidance which requests several clarifications on the evidence submitted by Sanofi, which is looking to market Aubagio (teriflunomide) as a ...
Read more : NICE demands more data for Sanofi's oral MS drug Aubagio | Views : 3968 | Replies : 0


EU grants marketing authorization for teriflunomide for MS

European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide).

Genzyme, announced that the European Commission has granted marketing authorization for Aubagio®(teriflunomide) 14 mg, a once-daily, oral therapy indicated for the treatment of adult MSers with relapsing remitting multiple sclerosis (RRMS)....... Read More - http://www.ms-uk.org/index.cfm/aubagio
Read more : EU grants marketing authorization for teriflunomide for MS | Views : 1033 | Replies : 0


aubagio with dinner

I am starting aubagio in a week or so if I get approved by the insurance company. I have been taking rebif for 5 years and always did the rebif around midnight. Since aubagio is suppose to be taken with a meal I wanted to take it with my dinner which is my biggest meal of the day and hopefully I would sleep through side effects like I did with the rebif. Is this a ...
Read more : aubagio with dinner | Views : 1994 | Replies : 5


Aubagio does not appear to affect immune response to flu vac

Aubagio does not appear to affect immune response to flu vaccination in MS patients

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.

Abstract

OBJECTIVE: To investigate the effect of teriflunomide on the efficacy and safety of seasonal influenza vaccine.... Read More - http://www.ms-uk.org/index.cfm/aubagio
Read more : Aubagio does not appear to affect immune response to flu vac | Views : 734 | Replies : 0


CHMP also Recommends NAS Designation for Aubagio®

Genzyme receives positive CHMP opinion for Lemtrada™ (alemtuzumab) in Europe

CHMP also Recommends NAS Designation for Aubagio® (teriflunomide) Following Positive Opinion on Approval in March 2013

Genzyme announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Lemtrada™ (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging ...
Read more : CHMP also Recommends NAS Designation for Aubagio® | Views : 3096 | Replies : 0


Aubagio and Hair Loss side effect

I am on month 5 of aubagio (used to take avonex). Everything was great until my hair started shedding! I am freaking out about it. I called Genzyme and all they could tell me was that for "most" people it eventually grew back. No other data available. It is not coming out in clumbs - just shedding all the time. I have very long hair - but my brush is full every 2 days! Anyone ...
Read more : Aubagio and Hair Loss side effect | Views : 4975 | Replies : 35


Aubagio® delays onset of clinically definite MS, study

Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
Read more : Aubagio® delays onset of clinically definite MS, study | Views : 965 | Replies : 0


 

Login  •  Register


Statistics

Total posts 220817 • Total topics 22883 • Total members 14451


Contact us | Terms of Service